Our Pricing

Allerief Weight Loss Treatment UK

Published on: June 03, 2026

Searching for allerief weight loss treatment uk options? At Cured Pharmacy, our UK-registered clinical team provides expert guidance on prescription weight loss treatments including Orlistat, GLP-1 receptor agonists, and evidence-based alternatives. All treatments require a free online consultation with our UK prescribers, completed in under 3 minutes.

Understanding Prescription Weight Loss Treatments in the UK

Weight loss medications licensed by the MHRA work through different mechanisms to support clinically significant weight reduction when combined with lifestyle modifications. The most commonly prescribed treatments in the UK include lipase inhibitors like Orlistat, which reduce dietary fat absorption by approximately 30%, and GLP-1 receptor agonists such as semaglutide and tirzepatide, which regulate appetite and glucose metabolism [1].

Clinical trials demonstrate that prescription weight loss medications produce substantially greater results than diet and exercise alone. In the STEP trials, patients using semaglutide achieved average weight reductions of 14.9% over 68 weeks, whilst the SURPASS-3 trial showed tirzepatide users lost an average of 22.5% body weight over 72 weeks [2][3]. These medications require ongoing prescriber supervision and are typically prescribed alongside structured dietary and physical activity programmes.

How Orlistat-Based Treatments Work

Orlistat functions as a gastrointestinal lipase inhibitor, blocking the enzyme responsible for breaking down dietary fats in the intestine. This mechanism prevents approximately one-third of consumed fat from being absorbed, resulting in reduced calorie intake when taken with meals containing fat [4].

Available in both 60mg over-the-counter formulations and 120mg prescription-strength capsules, Orlistat is typically prescribed for adults with a BMI of 30 or above, or 28 or above with weight-related health conditions. Clinical studies show average weight loss of 5-10% of initial body weight over 12 months when combined with a reduced-calorie diet [4]. At Cured Pharmacy, Orlistat starts from £135.00, with branded options including Xenical from £135.00 and Orlos 60mg from £135.00.

Managing Orlistat Side Effects

The most common side effects relate to unabsorbed fat passing through the digestive system, including oily stools, increased bowel movements, and occasional faecal urgency. These effects typically diminish when patients follow a lower-fat diet (less than 30% of calories from fat) and often resolve within the first few weeks of treatment. Our UK prescribers provide detailed dietary guidance to minimise these effects whilst maximising treatment efficacy.

GLP-1 Receptor Agonists: Advanced Weight Loss Options

GLP-1 (glucagon-like peptide-1) receptor agonists represent the most effective prescription weight loss class currently available in the UK. These injectable medications mimic a natural hormone that regulates appetite, slows gastric emptying, and improves insulin sensitivity [2]. The three main options licensed for weight management are liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Mounjaro).

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist, activating two complementary hormone pathways rather than one. This dual mechanism produces superior weight loss outcomes compared to single-pathway GLP-1 treatments. In head-to-head trials, tirzepatide demonstrated 20-25% greater weight reduction than semaglutide at comparable timepoints [3]. At Cured Pharmacy, Mounjaro starts from £135.00, Wegovy from £135.00, and Saxenda from £135.00, with dosing determined by your UK prescriber during consultation.

Comparing Injectable Weight Loss Treatments

Saxenda requires daily injections and is typically prescribed as an initial GLP-1 option due to its established safety profile and lower starting cost. Wegovy and Mounjaro are administered once weekly, offering greater convenience and higher average weight loss percentages in clinical trials. Your prescriber will assess your medical history, weight loss goals, previous treatment responses, and budget to recommend the most appropriate option. All three medications require gradual dose escalation over several weeks to minimise gastrointestinal side effects.

Eligibility Criteria for Prescription Weight Loss Medications

NICE guidelines recommend prescription weight loss treatments for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [5]. Lower BMI thresholds (28 kg/m² for Orlistat, 27 kg/m² for GLP-1 agonists) apply to patients of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family background due to increased metabolic risk at lower body weights.

During your free online consultation at Cured Pharmacy, our UK prescribers assess your full medical history, current medications, previous weight loss attempts, and any contraindications. Certain conditions preclude the use of specific treatments — for example, GLP-1 receptor agonists are not suitable for patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Treatment is only approved when clinically appropriate and safe for your individual circumstances.

Combining Medication with Lifestyle Modifications

Prescription weight loss medications are most effective when integrated into a comprehensive programme including dietary changes, increased physical activity, and behavioural support. Clinical trial participants who achieved the greatest weight reductions consistently combined medication with structured lifestyle interventions [2][3]. Our UK clinical team provides guidance on evidence-based dietary approaches and realistic activity goals tailored to your starting fitness level.

Patients using Orlistat benefit from following a balanced, reduced-calorie diet with moderate fat content (approximately 30% of total calories) distributed evenly across three main meals. Those prescribed GLP-1 receptor agonists often find appetite suppression makes calorie restriction easier to maintain, but adequate protein intake (1.2-1.6g per kg of ideal body weight) remains essential to preserve lean muscle mass during weight loss. Regular monitoring through follow-up consultations ensures treatment remains effective and side effects are appropriately managed.

Setting Realistic Weight Loss Expectations

Sustainable weight loss typically occurs at 0.5-1kg per week, though initial losses may be higher due to fluid changes. Treatment is generally continued if patients achieve at least 5% weight loss within 12 weeks on Orlistat, or show consistent progress on GLP-1 agonists during the titration phase. Long-term success requires ongoing commitment to lifestyle changes, as weight regain commonly occurs if medication is discontinued without maintained behavioural modifications. Our prescribers provide realistic goal-setting support based on your individual circumstances and treatment response.

Why Choose Cured Pharmacy for Weight Loss Treatment

As a fully registered UK pharmacy (GPhC 9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073), Cured Pharmacy provides transparent upfront pricing with no hidden consultation fees. You'll see exact treatment costs before completing your clinical assessment, and our lowest price guarantee ensures you're receiving competitive UK pricing on genuine MHRA-licensed medications.

Our streamlined online consultation takes under 3 minutes and is reviewed by UK-registered prescribers who specialise in weight management. Approved prescriptions are dispensed from our registered pharmacy premises and delivered in 100% discreet packaging with tracked courier services. Ongoing prescription renewals are managed through your secure patient account, with regular check-ins to monitor progress and adjust treatment as needed. For clinical questions or prescription support, our pharmacy team is available on (+44) 116 4646009 during business hours.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. Sjöström, L., et al. (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet, 352(9123), 167–172. https://doi.org/10.1016/S0140-6736(97)11509-4 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.